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Multifunctional role of Erk5 in multiple myeloma
Xonia Carvajal-Vergara, Soraya Tabera, Juan C. Montero, Azucena Esparı´s-Ogando, Ricardo Lo´pez-Pe´rez, Gema Mateo, Norma Gutie´rrez,
Marisa Parmo-Caban˜as, Joaquı´n Teixido´, Jesu´s F. San Miguel, and Atanasio Pandiella
Multiple myeloma is characterized by the
accumulation of terminally differentiated
B cells in the bone marrow, due to in-
creased proliferation and restricted apo-
ptosis of the myelomatous clone. Here we
have studied the participation of a novel
mitogen-activated protein kinase (MAPK)
route, the extracellular signal-regulated
kinase 5 (Erk5) pathway, in the regulation
of myeloma cell proliferation and apopto-
sis. Erk5 was expressed in cells isolated
from patients and in myeloma cell lines.
The myeloma growth factor interleukin 6
(IL-6) activated Erk5, and this activation
was independent of Ras and Src. Expres-
sion of a dominant-negative form of Erk5
restricted the proliferation of myeloma
cells and inhibited IL-6–dependent cell
duplication. This dominant-negative form
also sensitized myeloma cells to the pro-
apoptotic action of dexamethasone and
PS341. The latter compound caused a
profound decrease in the amount of en-
dogenous Erk5 and was less effective in
inducing apoptosis when the level of Erk5
was increased by transfection of Erk5.
These results place the Erk5 route as a
new regulatory signaling pathway that
affects multiple myeloma proliferation and
apoptosis. (Blood. 2005;105:4492-4499)
© 2005 by The American Society of Hematology
Introduction
Multiple myeloma (MM) is a clonal B-cell neoplasm characterized
by the accumulation of terminally differentiated B cells (plasma
cells [PCs]) in the bone marrow.1 Even though substantial advances
in the treatment of MM have been made during recent years,
complete eradication of the malignant clone is still not possible.1
Accordingly, new relevant areas of research focus on the incorpora-
tion of novel drugs into MM treatment, and the better knowledge of
the mechanisms that control MM proliferation and survival.2 With
respect to the latter, several studies have implicated the signal
transducer and activator of transcription 3 (STAT3) and phosphati-
dylinositol 3-kinase (PI3K)/Akt routes in the survival of MM
cells.3 In addition, the mitogen-associated protein kinases (MAPKs)
have been also involved in the control of the proliferation/survival
of MM cells.3 Three classical MAPK pathways have been de-
scribed in mammals.4-6 One, which includes the extracellular signal-
regulated kinases 1 and 2 (Erk1 and Erk2), is activated by growth
factors and has been linked to the stimulation of cell proliferation in
several cellular systems,5,6 including MM cells.7 The 2 other
MAPK routes, the p388 and the Jun N-terminal kinases (JNK)
pathways,9 are mainly triggered by cytokine and stress stimuli, and
their activation has been shown to regulate apoptotic responses.10
A recently characterized MAPK, the Big MAPK-1/Erk5, has
recently been implicated in the control of proliferation,11-14 partici-
pates in cellular responses to oxidative and mechanical stresses,15,16
and regulates apoptotic responses.17 In vivo studies have indicated
that Erk5 may support vascular endothelial viability in the adult
animal18 and critically participates in embryogenesis, probably due
to its role in proliferation and angiogenesis/vasculogenesis.19-21
Erk5 shares homology with Erk1/2 but is substantially higher in
molecular weight, due to the presence of a C-terminal extension
that is absent in Erk1/2.22,23 In analogy to Erk1/2, activation of Erk5
occurs by dual phosphorylation at the threonine (Thr218) and
tyrosine (Tyr220) residues present in the TEY sequence of the
activation loop.13 Phosphorylation at these sites is carried out by
the upstream MAP/ERK kinase Mek5, which is specific for Erk5.22
How activated receptors couple to Erk5 is still unclear. In fact,
growth factor receptors may cause Erk5 activation through Ras in
certain cell lines,24,25 but not in others.13 In addition, other
intracellular kinases, such as MEK kinase 2/3 (MEKK2/3),26
c-Cot,27 and c-Src28 may also regulate the activation of the Erk5
cascade. Signaling downstream of Erk5 involves phosphorylation
of substrate targets as well as a direct action of Erk5 on gene
expression, due to the presence of a transactivation domain in the
unique C-terminus of Erk5.29 Important substrates of Erk5 are the
serum and glucocorticoid-induced kinase,30 and transcription fac-
tors of the myocyte enhancer factor 2 (MEF2) family.31 The latter
includes 4 proteins (MEF2A, B, C, and D),32 and 3 of them
(MEF2A, C, and D) act as Erk5 substrates.33 Phosphorylation of
MEF2 factors by Erk5 has been shown to regulate the expression of
other transcription factors, such as c-Jun, that participate in cell
cycle progression.34 In addition, MEF2 factors have been reported
to mediate the antiapoptotic action of Erk5.35
Because of the important roles of the Erk5 route in the control of cell
proliferation in several tissues and in tumoral cells, we investigated the
expression and function of Erk5 in MM. Here, we show that MM cells
express Erk5 and that this MAPK can be activated by IL-6. Expression
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of a dominant-negative form of Erk5 restricted the proliferative re-
sponses caused by IL-6 and favored drug-induced apoptosis of my-
eloma cells. Therefore, our data identify Erk5 as a novel route activated
by IL-6 and indicate that Erk5 has multiple functions in MM, including
the regulation of a proliferative and antiapoptotic response.
Materials and methods
Materials and immunochemicals
Cell culture media, sera, and penicillin-streptomycin were purchased from Gibco
BRL (Gaithersburg, MD). Protein A-Sepharose was from Amersham-Pharmacia
(Piscataway, NJ). Immobilon P membranes were from Millipore (Bedford, MA).
PD98059, FPTIII, GGTI, PP2, Z-IETD-FMK, Z-LEHD-FMK, and Z-VAD-
FMK were from Calbiochem (San Diego, CA). IL-6, epidermal growth factor
(EGF), stem cell factor (SCF), tumor necrosis factor  (TNF-) and insulin-like
growth factor 1 (IGF-1) were from Strathmann (Hamburg, Germany). PS341
was from Millennium Pharmaceuticals (Cambridge, MA). Other generic chemi-
cals were purchased from Sigma Chemical (St Louis, MO), Roche Biochemicals
(Mannheim, Germany), or Merck (Darmstadt, Germany). Neuregulin (NRG)
was generously provided by Dr Mark X. Sliwkowski (Genentech, San Francisco,
CA). The anti-pMEK1 was from Cell Signaling (Beverly, MA). The anti-Erk1/2,
anti-pErk1/2, anti–H-Ras, anti-Mek5, antitubulin, and anti-PY99 antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-pAkt, anticaspase-3,
and anti–c-Kit antibodies were from Becton Dickinson (San Diego, CA). The
anti-HA antibody was from Roche Biochemicals. The anti-pMek5 antibody was
generously provided by Dr N. Mody (University of Dundee, Scotland).36 The
cyanine 3 (Cy3)–conjugated secondary antibody was from Jackson ImmunoRe-
search (West Grove, PA). The horseradish peroxidase (HRP)–conjugated second-
ary antibodies were from Bio-Rad (Hercules, CA). The anti-Erk5 antibodies have
been described previously.12
Cell culture and transfections
The cell lines MM1S, MM1R (from Dr S. T. Rosen, Chicago, IL); MM144,
OPM2 (from Dr S. Rudikoff, Bethesda, MD); NCIH929 (from Dr J. Teixido´,
Madrid, Spain); U266, and RPMI8226 (from Dr W. Dalton, Tampa, FL)
were cultured at 37°C in a humidified atmosphere in the presence of 5%
CO2-95% air. Cells were grown in RPMI 1640 medium with L-glutamine,
penicillin (100 U/mL), streptomycin (100 g/mL), and 10% (cell lines) or
20% (patient cells) fetal bovine serum (FBS). For the biochemical
experiments, and unless otherwise indicated, myeloma cells were treated in
complete media that had been with the cells for at least 24 hours.
Generation of retroviruses and infection
293T cells were plated in 60-mm–diameter dishes (1.8 106 cells in 3 mL
Dulbecco modified Eagle medium [DMEM] with 10% FBS) and allowed to
attach overnight. Five minutes prior to transfection, 25 M chloroquine was
added to each plate. The transfection solution contained DNA (2.5 g pMDG-
VSV, 5 g pNGVL-MLV-gag-pol, 3 g retroviral vector [pLZR-IRES-GFP,
pLZR-HA-Erk5AEF-IRES-GFP, or pLZR-RasN17-IRES-GFP]), 61 L 2 M
CaCl2, and doubled-distilled H2O to 500 L. After mixing, 0.5 mL of 2
hepes-buffered saline solution (HBS) (pH 7.0) was added, and the solution was
bubbled for 15 seconds. The HBS-DNA complex was dropped onto cells. Eight
hours later, this medium was replaced with complete culture medium that was
replaced 24 to 32 hour after transfection with 3 mL fresh virus-collecting
medium. Twenty-four hours later, the supernatant from transfected cells was
centrifuged at 1000g for 5 minutes. MM1S or MM144 cells were infected with 1
mL viral supernatants containing Polybrene at 6 g/mL, to which 9 mL RPMI
1640 with 10% FBS medium was added 1 hour later. The following day, the
medium was changed to overnight-infected MM cells.
Cell proliferation assays
The analysis of MM cell proliferation using the methylthiotetrazole (MTT)
assay has been described previously.37 Four wells were analyzed for each
condition, and the results are presented as the mean SD of quadruplicates
of a representative experiment that was repeated at least twice. Annexin
V–fluorescein isothiocyanate (FITC) measurements and analysis of apopto-
tic cell death were performed as described.37 Measurement of cell
proliferation of myeloma cells cocultured with bone marrow stromal cells
(BMSCs) was carried out as described previously.38 Briefly, BMSCs were
plated in 96-well culture dishes (50 000/well) and allowed to reach
confluence during 48 hours. Then, 30 000 myeloma cells were plated in
RPMI 1640 containing 0.5% serum. Bromodeoxyuridine (BrdU) was added
for the last 8 hours, and then BrdU uptake was measured using a
commercial kit (Roche Biochemicals), following the manufacturer’s
instructions.
Reporter gene analysis
Plasmids encoding a luciferase gene driven by the wild-type Nur77
promoter (pMEF2-luc-wt that contains the 307 to 242 region of the
Nur77 promoter), or a Nur77 promoter with mutated MEF2-binding sites
(pMEF2-luc-mut)29,39 were provided by Dr A. Winoto (University of
California, Berkeley, CA). These luciferase constructs were cotransfected
with pRLSV40 Renilla vector to control for transfection efficiency, in a
molar ratio of 1:40 (pRLSV40 versus pMEF2-luc-wt or pMEF2-luc-mut
vectors). Then, 20  106 MM1S cells were transfected by electroporation
with 5 g of the indicator plasmid or the mutated version. Electroporation
was performed in serum- and antibiotics-free media with a Gene Pulser II
apparatus (Bio-Rad) using 0.4-cm gene pulser cuvettes (Bio-Rad) with
settings of 250 V and 950 F. Eighteen hours after transfection, cells were
rinsed with phosphate-buffered saline (PBS) and harvested with Passive
Lysis buffer (Promega, Madison, WI). The Dual Luciferase System
(Promega) was used according to the manufacturer’s protocol. Readings
were taken in duplicate in a luminometer (BERTHOLD, Pforzheim,
Germany), and experiments were repeated 3 times.
Immunoprecipitation, Western blotting, and
immunofluorescence microscopy
Cells were collected and centrifuged at 10 000g for 2 minutes. Then cells
were washed with PBS and lysed in ice-cold lysis buffer (140 mM NaCl,10
mM EDTA [ethylenediaminetetraacetic acid], 10% glycerol, 1% Nonidet
P-40, 20 mM Tris [tris(hydroxymethyl)aminomethane], pH 7.0, 1 M
pepstatin, 1 g/mL aprotinin, 1 g/mL leupeptin, 1 mM sodium orthovana-
date). Samples were centrifuged at 10 000g at 4°C for 10 minutes and
supernatants were transferred to new tubes with the corresponding antibody
and protein A-Sepharose. The rest of the immunoprecipitation and Western
blotting protocol was carried out as described before.40
For immunofluorescence microscopy, myeloma cells were plated on
poly-L-lysine–pretreated glass coverslips. Attached cells were subsequently
washed with PBS and fixed in 2% P-formaldehyde for 30 minutes at room
temperature. The rest of the protocol for the staining and confocal
microscopy has been described.12
Ras binding to GST-RafRBD
Cells were stimulated for 15 minutes with 5 nM IL-6 and lysed with
ice-cold lysis buffer containing 25 mM HEPES (N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid), pH 7.5. After centrifugation at 12 000g for
10 minutes, cellular extracts were precipitated with 15 g GST-RafRBD
(gluthione-S-transferase-Raf Ras binding domain fusion protein) for 30
minutes at 4°C. Samples were then washed 3 times with lysis buffer,
resuspended in 2  sample buffer, and boiled for 5 minutes. The samples
were run in 12% gels and Ras bound to the fusion protein was analyzed by
Western blotting.
In vitro kinase analyses
Extracts from MM1S cells treated with IL-6 or IGF-1 were immunoprecipi-
tated with the anti-Erk2 antibody, and immunocomplexes were washed 3
times with lysis buffer. A final wash was performed with kinase buffer (20
mM HEPES, pH 7.6, 20 mM MgCl2, 25 mM -glycerophosphate). The
immunocomplexes were then incubated for 30 minutes at 30°C with 2 g
GST-Elk in the kinase buffer containing 10 M adenosine triphosphate
Erk5 IN MYELOMA 4493BLOOD, 1 JUNE 2005  VOLUME 105, NUMBER 11
For personal use only.on June 4, 2016. by guest  www.bloodjournal.orgFrom 
(ATP), 1 Ci (-32P)ATP (0.037 MBq). Samples were electrophoresed in
10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) gels and bands in dried gels detected by autoradiography.
RT-PCR and quantitative PCR
RNA was isolated from MM1S cells, and an equal amount (2 g) from the
different samples was primed with poly-T. cDNA was synthesized with M-MLV
reverse transcriptase (RT; Promega). The relative levels of gene expression were
determined by real-time quantitative polymerase chain reaction (PCR) based on
2-step SYBR green I chemistry. As reference genes for normalization of the
expression data, we used ABL and GAPDH. The primers used were: c-Jun:
5-AAAAGTGAAAACCTTGAAAGCTCAG-3 and 5-CGTGGTTCAT-
GACTTTCTGTTTAAG-3;ABL: 5-CCATGAGGTACTGGTCCCTTC-3 and
5-CGCCACTTAGAAAAGAGCGTC-3; GAPDH: 5-CAGGGCTGCTTT-
TAACTCTGGTAA-3 and 5-GGGTGGAATCATATTGGAACATGTA-3;
MEF2A: 5-AGTCTCACTCTACCCCCCAGG-3 and 5-GCTACTCGGGAG-
GCTTGAGGT-3; MEF2B: 5-AGCACAAGGCAGACATGCAG-3 and 5-
TGTCCACCAGGTTCTTCACG-3; MEF2C: 5-ACTTGAGCACACGC-
GGTACACC-3 and 5-TCCACCTGATTCAAACATGCAG-3; MEF2D:
5-CGCTCTTTGCCGTGACAAC-3and 5-ACGGTCTGGGAACAGTGCTC-
3; MEKK2: 5-AAACGGCTTCAGACCATCTGTC-3 and 5-CCATAGCCTT-
GTCCACTGATGA-3; MEKK3: 5-GAGAGCCCGAGGAGGTGTCT-3 and
5-GGACACAGCTGGTGGTAGCA-3; c-cot: 5-ACTGGTTGAGCCCAA-
GAGTTCA-3 and 5-GACTACAGGCATGCACCATCAC-3.
Statistical analysis
The Student t test was used for comparisons between means. P 	 .01 was
interpreted to denote statistical significance. The statistical analysis was
performed using the SPSS 11.0 statistical package (SPSS, Chicago, IL).
Results
Expression of Erk5 in myeloma cells
To investigate a possible role of Erk5 in MM biology, we first
analyzed whether myeloma cells expressed this MAPK. For this
purpose, lysates from different MM cell lines were prepared and
immunoprecipitated with an antibody raised to the C-terminus of
Erk5 (residues 781-805; Figure 1A; see also Esparis-Ogando et
al12), and Erk5 expression was analyzed by Western blotting. As
shown in Figure 1B, the antibody recognized 2 different bands. A
faster migrating band of 120 kDa of Mr was present at different
levels in all the cell lines analyzed. This band corresponds to a form
of Erk5 that is devoid of phosphorylation at the TEY microdomain
within the Erk5 activation loop12 and is considered to represent
inactive Erk5. In addition, a slower migrating Erk5 form was also
detected in MM1S (Figure 1B), although its amount was much
lower. The Erk5 forms were absent when the antibody was
preincubated with an excess of the peptide used for the raising of
the antibody, indicating that the antibody specifically recognized
Erk5 (Figure 1C). Erk5 was also expressed in bone marrow plasma
cells from 3 patient samples examined (Figure 1D).
The subcellular distribution of Erk5 in myeloma cells was studied by
immunofluorescence microscopy with the anti-Erk5 C-terminal anti-
body. Strong staining of Erk5 was observed in the cytosolic compart-
ment (Figure 1E, top panels), and this staining was prevented by
preincubation of the antibody with the Erk5 peptide (Figure 1E, bottom
panel). On higher magnification analysis, some staining was also
observed in the nucleus, where Erk5 accumulated in certain regions
following a dotted pattern (data not shown).
Erk5 is activated by IL-6
Because Erk5 is activated by factors that control cell proliferation/
survival in other cell types,14 the activation of Erk5 by different
cytokines known to affect these processes in MM cells was
investigated. Treatment with IL-6 caused a retardation in the
mobility of Erk5, indicative of Erk5 dual phosphorylation, in
MM1S (Figure 2A, top panel) and in MM144 cell lines (Figure 2B,
top panel), as well as in patient cells (Figure 2C). The dual Erk5
phosphorylation following IL-6 stimulation was confirmed by
immunoprecipitation of MM cell lysates with an antibody that only
detects phosphorylated Erk5 (data not shown). IL-6 also induced
Erk1/2 phosphorylation in MM1S and MM144 cell lines (Figure
2A-B, middle panels), as well as phosphorylation of the Erk5
upstream element Mek5 (data not shown). Interestingly, IGF-1,
which has been reported to stimulate MM cell proliferation,41,42 did
not substantially induce Erk1/2 or Erk5 dual phosphorylation in
MM1S, MM144, and OPM2 cells (Figure 2D). In NCIH929, IGF-1
also failed to substantially induce Erk5 phosphorylation; however,
and in agreement with previously published data,43 IGF-1 activated
Erk1/2 in these cells. Time-course experiments carried out in
MM1S cells confirmed that IL-6 stimulated Erk1/2 phosphoryla-
tion and activity (the latter measured by in vitro kinase analyses
using GST-Elk as a substrate; Figure 3A), whereas IGF-1 failed to
induce any substantial increase in Erk1/2 phosphorylation or
activity. However, both IL-6 and IGF-1 stimulated Akt phosphory-
lation (Figure 3A).
Figure 1. Expression of Erk5 in myeloma cells. (A) Schematic representation of
Erk5, with the epitopes recognized by the anti-Erk5 (C-terminal), anti-pErk5, and
anti-HA antibodies. (B) Expression of Erk5 in MM cell lines. Erk5 was immunoprecipi-
tated from 1-mg cell extracts and detected by Western blotting with the anti–
C-terminus antibody. The position of the Mr markers is indicated at the right. In
parallel, and as a loading control, 20 g protein from each of the cell extracts was
analyzed for tubulin content by Western blotting. (C) Specificity of the anti-Erk5
antibody; 1 mg MM1S cell extracts was immunoprecipitated with the anti-Erk5
C-terminus antibody either in the absence or presence of 10 g of the peptide used to
raise the antibody. Erk5 was detected by Western blotting as described in panel B. (D)
Expression of Erk5 in patient myeloma cells. Cells were isolated from myeloma
patients, plated in complete media, and analyzed by Western blotting for Erk5. The
proportion of malignant plasma cells was greater than 90% as indicated by
phenotypic analysis before the experiment. (E) Immunofluorescent localization of
Erk5 in myeloma cells. Cells were plated on poly-L-lysine–coated coverslips and
immunostained with the anti-Erk5 C-terminal antibody that was previously preincu-
bated with the antigenic peptide, where indicated. Erk5 is shown in red, together with
a nuclear stain (SYBR green). Bar represents 10 m.
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Ligands of EGF family, that act through ErbB receptors,
activate Erk5 in other cellular systems,12,13 and have been shown to
regulate proliferation of MM cells.44 Two of these ligands, EGF
and NRG, failed to activate Erk5 in MM1S and MM144 cells.
Furthermore, addition of EGF or NRG failed to induce activation
of ErbB receptors in MM1S, MM144, and U266 cells (data not
shown). SCF, an activator of the c-Kit receptor tyrosine kinase,
which is present in malignant plasma cells from about 20% of the
patients with MM,45 also failed to induce Erk5 activation in MM1S
and MM144 cells (Figure 2A-B). IL-6–induced phosphorylation of
Erk5 was maximal at concentrations of the cytokine of 5 nM and
above and was noticeable at 1 nM (Figure 3B).
IL-6–induced Erk5 activation occurs through a Ras- and
Src-independent pathway that is sensitive to classical MEK1/2
inhibitory compounds
To investigate if Ras was involved in IL-6–induced Erk5 phosphor-
ylation, MM1S cells were infected with a retroviral vector that
contained a form of H-Ras (RasN17) that acts as a dominant-
negative form.12,13 Western blotting with an anti–H-Ras antibody
showed that the infected cells expressed the mutated RasN17
protein (Figure 4A, bottom panel). IL-6–induced phosphorylation
of Erk5 was of similar magnitude in cells expressing RasN17 when
compared to control cells (Figure 4A, top panel). In contrast, the
phosphorylation of Erk1 and Erk2, which lie downstream of Ras,
was significantly inhibited (Figure 4A, second panel). Quantitative
analyses indicated that the presence of RasN17 resulted in a 60%
inhibition of IL-6–induced Erk1/2 phosphorylation, without affect-
ing Erk5 phosphorylation (Figure 4B). Another strategy used to
assess whether Ras participated in Erk5 activation was based on the
use of farnesyltransferase or geranylgeranyltransferase inhibitors.
Pretreatment with the farnesyltransferase inhibitor, FPTIII, only
marginally affected Erk5 phosphorylation in response to addition
of IL-6 (Figure 4C, top panel), but decreased Erk1/2 phosphoryla-
tion (Figure 4C, middle panel). Quantitative analyses of these data
showed the stronger effect of FPTIII on Erk1/2 phosphorylation, as
compared to Erk5 phosphorylation (Figure 4D). Pretreatment with
the geranylgeranyltransferase inhibitor, GGTI, did not significantly
affect Erk5 activation by IL-6 (data not shown).
Src has been involved in the activation of Erk5 in other cellular
systems.28,46 In MM cells treated with PP2, a compound that
inhibits Src kinase activity, and Src-mediated Erk5 activation in
other cell types,28,46 the compound was unable to prevent IL-6–
induced Erk5 phosphorylation (Figure 4E), suggesting that Src did
not play a major role in the activation of Erk5 by IL-6.
The homology between Erk1/2 and Erk5 led us to analyze
whether inhibitors of the Erk1/2 route also acted as regulators of
Erk5 activation in myeloma cells. Preincubation of MM1S cells
with PD98059, a Mek1/2 inhibitor, impaired IL-6–induced phos-
phorylation of Erk1/2 and Erk5 (Figure 4F). Similar results were
obtained when using U0126, a different Mek1/2 inhibitor (data not
shown). As previously reported for other cell types,36 their inhibi-
tory action on Erk1/2 was more potent than on Erk5. The fact that
inhibitors of the activation of Erk1/2 affected the activation of Erk5
raised the possibility that the Mek1/2-Erk1/2 route could act
upstream of the Erk5 route. To analyze this, we used an alternative
treatment to activate the Mek1/2-Erk1/2 route. Protein kinase C
(PKC) activation by phorbol esters, such as phorbol myristate
acetate (PMA), has been reported to cause Erk1/2 activation by
stimulation of Ras.47 In MM1S cells addition of PMA or IL-6
induced a clear activation of Ras (Figure 4G). The activation of Ras
was followed by increased phosphorylation and activation of Mek1
and Erk1/2, and the degree of activation was higher in cells treated
with the phorbol ester, as compared to cells that received IL-6
(Figure 4G and data not shown). However, PMA failed to induce
Erk5 dual phosphorylation. These data exclude a link between the
Mek1-Erk1/2 route and the Erk5 pathway. Furthermore, the fact
that PMA activated Ras without causing Erk5 phosphorylation,
together with the data using RasN17, clearly dissociate Ras
activation from Erk5 phosphorylation in myeloma cells.
MEF2 factors are expressed in myeloma cells and act as
downstream Erk5 mediators
Because of the reported role of MEF2 proteins in Erk5 signal
transduction in other cellular systems,34,35 we investigated whether
Figure 3. Time course and dose response of IL-6–induced Erk5 activation in
myeloma cells. (A) Time course of the effect of IL-6 and IGF-1 on Erk1/2 activation and
phosphorylation and Erk5 and Akt phosphorylation. MM1S cells were treated for the
indicated times with the growth factors and cell extracts used for analyses of Erk1/2 activity
using GST-Elk, Erk1/2, pErk1/2, or pAkt in Western blots of cell extracts. Erk5 was detected
by Western blotting of anti-Erk5 immunoprecipitates. The panels show the results of an
experiment that was repeated twice. (B) Dose effect of IL-6 on Erk5 phosphorylation. IL-6
was added for 15 minutes, and Erk5 was analyzed as in panelA.
Figure 2. IL-6 activates Erk5 in myeloma cells. MM1S (A) or MM144 (B) cells were
incubated for 10 minutes with 10 nM EGF, IGF-1, IL-6, NRG, TNF-, or SCF, and Erk5
expression was analyzed by Western blotting. The action of the polypeptide factors
on Erk1/2 phosphorylation was detected by Western blotting with anti-pErk1/2
antibodies, and the total amount of Erk1/2 was analyzed on cell extracts with an
anti-Erk1/2 antibody. (C) Effect of IL-6 on patient myeloma cells. Cells were treated
with IL-6 as described in panel A and Erk5 analyzed by Western blotting from
anti-Erk5 immunoprecipitates. (D) Cells were serum-starved for 18 hours and then
treated with IGF-1 (10 nM) or IL-6 (5 nM) and Erk5 and pErk1/2 were analyzed by
Western blotting.
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MEF2 transcription factors were expressed in MM cells and
participated in Erk5 signal transduction. RT-PCR analyses showed
that MM1S and MM144 cells expressed MEF2A, MEF2C, and
MEF2D, whereas the expression of MEF2B was undetectable
(Figure 5A). To analyze the potential participation of MEF2
proteins in Erk5 signaling in MM cells, we used a luciferase
reporter system based on the Nur77 promoter, which contains
MEF2-binding sites.29,39 In addition, to regulate Erk5 function we
used a mutant HA-tagged version of Erk5 in which the TEY
microdomain was changed to AEF, creating a form of Erk5 that acts
as a dominant negative34 (HA-Erk5AEF, Figure 1A, see also
Esparis-Ogando et al12). HA-Erk5AEF was subcloned into the
retroviral vector pLZR-IRES-GFP and particles used to infect
MM1S cells. Western blotting with the anti-HA antibody identified
the HA-Erk5AEF form in cells infected with pLZR-HA-Erk5AEF-
IRES-GFP, but not in pLZR-IRES-GFP–infected cells (Figure 5B,
top panel). Western blotting using the anti-Erk5 antibody indicated
that the expression of HA-Erk5AEF was above the levels of
endogenous Erk5 (Figure 5B, bottom panel).
IL-6 increased luciferase activity in MM1S cells transfected with the
MEF2 indicator plasmid pMEF2-luc-wt (Figure 5C). In cells expressing
the dominant-negative form of Erk5, treatment with IL-6 caused a
minimal increase in luciferase activity. IL-6 did not cause any significant
change in luciferase activity in MM1S cells transfected with a mutated
MEF2 indicator plasmid unable to bind MEF2 (pMEF2-luc-mut29).
These results indicated that MEF2 factors were expressed by MM cells
and that the Erk5-MEF2 axis may participate in the regulation of gene
expression by IL-6 in MM cells.
Expression of dominant-negative Erk5 restricts MM
proliferation and sensitizes MM cells to apoptosis
Because Erk5 has been involved in the control of cell proliferation
in other cell types14 and was activated by IL-6 in myeloma cells, its
potential role in MM proliferation was investigated. Expression of
HA-Erk5AEF significantly reduced MTT uptakes of MM1S cells
(Figure 6A). Furthermore, the MTT uptake of cells containing
HA-Erk5AEF started to decline after 6 days in culture, suggestive of
a reduction in cell number. The possible participation of Erk5 in
IL-6–induced proliferation was also analyzed. IL-6 slightly in-
creased MTT uptake of control MM1S cells after 24 hours, and this
effect was clearly observed at 3 days of treatment (Figure 6B). In
contrast, expression of HA-Erk5AEF resulted in a blockade of
IL-6–induced proliferation of MM1S cells. That this effect was due
to restricted proliferation of MM1S cells expressing HA-Erk5AEF
with respect to control cells was confirmed by analysis of DNA
synthesis by BrdU uptake experiments (Figure 6C).
We investigated whether Erk5 could be implicated in the regulation
of MM apoptosis. First, the sensitivity of MM cells expressing
HA-Erk5AEF to PS341 and dexamethasone, 2 clinically relevant agents
that induce MM apoptosis,1 was analyzed. Expression of HA-Erk5AEF
significantly increased the sensitivity of MM cells to the apoptotic action
of both PS341 and dexamethasone (Figure 7A). The increased sensitiv-
ity to PS341 was less evident when the myeloma cells were treated with
this compound in the presence of bone marrow stromal cells (Figure
7B). Interestingly, PS341 caused a significant decrease in the amount of
Erk5 in MM1S (Figure 7C, top panel) and MM144 cells (Figure 7C,
bottom panel), without substantially affecting Erk1/2 levels (Figure 7C,
middle panel). Dexamethasone also reduced the levels of Erk5 in
MM1S cells (data not shown). PS341 has been shown to decrease the
levels of the gp130 subunit of the IL-6 receptor through caspase
activation.48 We analyzed whether an analogous mechanism partici-
pated in PS341-induced down-regulation of Erk5. As shown in Figure
7D, the pan-caspase inhibitor Z-VAD-FMK, as well as the caspase-8
inhibitor Z-IETD-FMK strongly inhibited PS341-induced Erk5 down-
regulation, or caspase-3 processing. We reasoned that if PS341 de-
creased Erk5 and this was related to the sensitivity to apoptosis on
treatment with this drug, then raising the levels of wild-type Erk5 could
decrease the apoptotic action of PS341 in MM cells. To test this, we
transfected MM1S cells with wild-type Erk5 and selected a pool of
MM1S cells in which the endogenous amount of Erk5 was supple-
mented several-fold by exogenous HA-tagged Erk5 (Figure 7E). The
action of PS341 was then tested on MM1S cells transfected with empty
Figure 4. IL-6 activates Erk5 in myeloma cells through a Ras- and Src-
independent route. (A) MM1S cells were infected with pLZR-IRES-GFP or pLZR-
RasN17-IRES-GFP, and the expression of Ras was analyzed by Western blot of cell
extracts using an anti–H-Ras antibody (iv). The effect of IL-6 on Erk5 (i) and pErk1/2
(ii) is shown, as well as the total Erk1/2 levels (iii). The asterisk indicates a nonspecific
band that appears sometimes in the anti-pErk1/2 blots. (B) Quantitative analyses of
the levels of Erk5 phosphorylation () or pErk1/2 (f) in MM1S cells infected with
pLZR-IRES-GFP or pLZR-RasN17-IRES-GFP, and treated, where indicated, with
IL-6 (5 nM, 15 minutes). The results are represented as the mean  SD of 3 different
experiments, and considering as 100% the stimulation obtained with IL-6 in control
infected cells. The number (#) sign indicates P 	 .01. (C) Effect of FPTIII on Erk5
phosphorylation in MM1S cells. Cells were preincubated with FPTIII (10 M) for
24 hours and then treated with IL-6 for 15 minutes. Erk5, Erk1/2, and pErk1/2 were
analyzed as described in A. (D) Quantitative analyses of the effect of FPTIII on Erk5
() and Erk1/2 (f) phosphorylation. The results were quantitated as described for
panel B. The number sign (#) indicates P 	 .01. (E) Effect of the Src inhibitor PP2 on
IL-6–induced Erk5 activation. PP2 (20 M) was added to MM1S cells for the times
indicated and then cells were stimulated with IL-6 for 15 minutes. Erk5 was analyzed
as described in A. (F) Action of PD98059 on IL-6–induced Erk5 and Erk1/2
phosphorylation. MM1S cells were preincubated with the indicated concentrations of
PD98059 for 60 minutes, and then IL-6 added for an additional 15-minute period.
Erk5 and pErk1/2 were analyzed by Western blotting as described in A, and the
amount of phosphorylation quantitated and graphically represented at the bottom of
each panel. (G) Action of IL-6 and PMA on Ras, Mek1, Erk1/2, and Erk5. MM1S cells
were treated with IL-6 (5 nM) or PMA (1 M) for 15 minutes and then lysates prepared
for Ras pull-down using GST-RafRBD, pMek, or pErk1/2 analyses on Western blots of
cell extracts, or Erk5 analysis on Western blots of anti-Erk5 immunoprecipitates.
Results are representative of an experiment that was repeated 3 times.
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vector (pCDNA3) or with pCDNA3-HA-Erk5. As shown in Figure 7E,
overexpression of HA-tagged wild-type Erk5 protected MM cells from
PS341-induced apoptosis.
Discussion
Aberrant control of plasma cell proliferation/survival lies at the
origin of MM and is responsible for the progression of this disease.
Therefore, a better understanding of the molecular mechanisms that
control these processes is critical for the development of biologi-
cally based therapies aimed at the eradication of the myelomatous
cells. Because the Erk5 route has been shown to regulate the
proliferation of other tumoral cells,14 we decided to analyze the role
of this MAPK route in MM. Here, we describe the expression of
Erk5 in MM cells and show the role of this kinase as a regulator of
MM proliferation and survival. In addition, we demonstrate that
Erk5 acts downstream of IL-6 in myeloma cells, adding this MAPK
route to the complex IL-6 signal transduction scenario.
Erk5 was expressed at different levels in the MM cell lines and
patient cells analyzed. Studies with different polypeptide factors
known to have a role in MM biology showed that IL-6 acted as a
regulator of Erk5. This cytokine plays an important function in MM
cell proliferation and survival3 and had a clear stimulatory effect on
Erk5 activation in both MM cell lines and patient cells. Activation
of Erk5 by IL-6 occurs on binding of the cytokine to its
heterodimeric cell-surface receptor, composed of the gp80 and
gp130 subunits. Selectivity for the binding to IL-6 is provided by
gp80 because gp130 can also function as a subunit of other
cytokine receptors.49 gp130 is responsible for the initiation of the
cytosolic signal transduction cascade. It is therefore likely that
cytokines that use gp130 as part of their receptor signaling module
may also activate the Erk5 route. In line with this is the finding that
leukocyte inhibitory factor (LIF), a cytokine that also uses gp130,
has been shown to provoke Erk5 activation in cardiomyocytes.50
In contrast to IL-6, IGF-1 failed to substantially activate Erk1/2
or Erk5 in most of the cell lines analyzed, with the exception of
NCIH929 cells. IGF-1, however, was an excellent activator of the
Akt route, even better than IL-6. These differences in signaling
suggest that both factors may provoke their actions on MM cells
through different intracellular routes. In line with this hypothesis is
the fact that the Erk1/2 inhibitor PD98059 (that also inhibits the
Erk5 route) prevented IL-6–induced MM proliferation,7 whereas it
did not significantly affect IGF-1–induced MM proliferation.43 The
latter effect of IGF-1 in MM cells is sensitive to the PI3K inhibitor
LY294002 and to the mammalian target of rapamycin (mTOR)
inhibitor rapamycin, indicating a predominant role of the Akt route
in IGF-1–induced proliferation of MM cells.
Although in other cellular systems growth factor–induced Erk5
activation can be regulated by Ras,25 IL-6–induced Erk5 phosphor-
ylation appeared to be Ras independent. Thus, expression of
RasN17, or treatment with farnesyltransferase and geranylgeranyl-
transferase inhibitors, agents that prevent H and N (FTI) and K-Ras
(GTI) activation,51 did not affect IL-6–induced Erk5 phosphoryla-
tion in myeloma cells. However, both treatments strongly affected
the phosphorylation of Erk1/2, known to reside downstream of
Ras. Because in other cell types RasN17 expression has been
shown to prevent Erk5 activation,25 it is likely that the differences
Figure 5. MEF2 participates in IL-6–Erk5 signal transduction. (A) Expression of MEF2 isoforms in MM1S and MM144 cells, analyzed by RT-PCR using primers specific for
each of the MEF2 isoforms. (B) Expression of a dominant-negative form of Erk5 in MM1S cells. Cells were infected with retroviruses that included an empty or
HA-Erk5AEF–containing vector, and the expression of the infected protein was analyzed by immunoprecipitation with the anti-Erk5 C-terminal antibody followed by blotting with
anti-HA (top) or anti-Erk5 (bottom) antibodies. (C) Effect of the dominant-negative form of Erk5 on an MEF2 luciferase reporter gene. MM1S infected with either the empty
retroviral vector or with the retroviral vector containing HA-Erk5AEF were electroporated with the indicated plasmid reporter gene and 24 hours later treated for 3 hours with IL-6
(5 nM; f) or not () as indicated. Cell extracts were prepared and analyzed for the relative luciferase activity as described in “Materials and methods.” Data are the mean SD
of duplicates of an experiment repeated twice.
Figure 6. Erk5 participates in MM proliferation. (A) Proliferation of MM1S (E) or MM1S cells expressing HA-Erk5AEF (F). Cells were plated at identical densities and MTT
uptake measured at the indicated times. Data correspond to the mean from quadruplicates  SD of an experiment that was repeated 3 times. *P 	 .01. (B) Action of
HA-Erk5AEF on IL-6–induced MM1S proliferation. Cells were plated at identical densities and IL-6 (5 nM; f) was added or not () where indicated. One day or 3 days after the
start of the experiment, MTT uptakes were measured. *P 	 .01. (C) Action of HA-Erk5AEF on IL-6–induced BrdU uptake. Control or HA-Erk5AEF–expressing MM1S cells were
plated at 50 000 cells/well, and then IL-6 was (f) added or not () for 3 days, where indicated. BrdU was added for the last 8 hours of the experiment, and then its uptake was
measured as described in “Materials and methods.” Results are presented as the mean from quadruplicates SD.
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in the participation of Ras in Erk5 activation of MM cells may
reflect a cell-specific mechanism. Another signaling molecule that
has been linked to the activation of Erk5 is Src. In vascular
endothelial cells, stresses such as stretching16 or oxidation28 cause
an increase in Erk5 activation through a Src-dependent route,
because the Erk5 response was sensitive to the Src inhibitor PP2.
Analogous results were also observed in pulmonary cells treated
with asbestos and preincubated with the Src antagonistic drug.46
However, in MM cells IL-6–induced Erk5 activation was insensi-
tive to PP2, suggesting that Src may not be involved in this process.
By contrast, PD98059 and U0126, which have been shown to
inhibit the Erk1/2 upstream activating enzymes Mek1 and Mek2,36
also efficiently inhibited IL-6–induced Erk5 phosphorylation, as
reported in other cellular systems.12,36 These results indicate that
these compounds may target the Erk5-activating kinases, or that
kinases participating in the Erk1/2 route may act upstream of Erk5.
The latter appears quite unlikely, especially in light of the results
obtained with PMA. This compound strongly activated Mek1
phosphorylation, as well as Erk1/2 phosphorylation and activity.
Yet activation of this pathway was not followed by Erk5 phosphor-
ylation, indicating that these 2 MAPK routes are not directly
linked. Furthermore, because PMA also activated Ras, without a
concomitant Erk5 phosphorylation, the data obtained with PMA
further support the idea that Erk5 phosphorylation is also unlinked
from Ras activation in MM cells.
The mechanism by which receptors couple to the Erk5 route has
only partially been uncovered. Evidence indicates that Mek5 acts as the
Erk5-activating kinase, and we have found that in fact this kinase is
phosphorylated by IL-6 in MM cells. Mek5, in turn, can be activated by
multiple upstream kinases, including c-cot,27 Mekk2,52 or Mekk3.26
Quantitative PCR analyses of the expression of c-cot, Mekk2, and
Mekk3 indicated analogous expression of Mekk2 and Mekk3 in MM1S
cells. These cells expressed very low levels of c-cot, suggesting that the
latter probably does not act as an important intermediate in IL-6–
induced Erk5 activation (R.L.-P. X.C.-V. and A.P., unpublished results,
June 2004). On the other hand, expression of a dominant-negative form
of Mekk3, created by mutating Lys391 to Trp391,26 did not affect
IL-6–induced Erk5 phosphorylation (X.C.-V. and A.P., unpublished
results, February 2005), indicating that Mekk3 activity may not be
required for IL-6 to activate Erk5. It is therefore possible that MEKK2,
or other kinases upstream of Mek5, may be intermediate in the action of
IL-6 on Erk5.Additional knowledge into the Erk5 field will be required to
identify the molecular components that link receptors to the Erk5 route.
Signaling downstream of Erk5 has been shown to include the
regulation of the activity of several transcription factors, especially
MEF2 family members. The latter factors have been shown to interact
with Erk531 and are phosphorylated at particular sites by Erk5.33 Our
analyses indicated that MEF2 proteins are expressed in MM cells and
may participate as mediators in the action of Erk5. Whether MEF2
proteins act in the control of MM survival, as reported in other cell
types,32,35 or in other aspects of MM biology will require future studies.
The use of a dominant-negative form of Erk5 uncovered multiple
functions of this MAPK in MM biology. Expression of the dominant-
negative form substantially affected IL-6–induced proliferation of
MM1S cells. This is in line with a role of Erk5 in growth factor/cytokine-
induced proliferation, as described in other systems.14 Several data
indicated that Erk5 may also participate in the control of MM apoptosis.
Expression of the dominant-negative form of Erk5 increased the
sensitivity of MM cells to PS341 and dexamethasone, 2 compounds that
effectively target MM cells.2 Furthermore, the levels of Erk5 were
down-regulated by PS341. This effect appears to be analogous to the
PS341-induced down-regulation of the gp130 subunit of the IL-6
receptor48 that occurs after caspase activation. In fact, the pan-caspase
and caspase-8 inhibitors prevented PS341-induced Erk5 down-
regulation. The down-regulation of Erk5 by PS341 was an unexpected
and interesting finding that suggested that the decrease of Erk5 could be
part of the action of PS341 in the induction of MM cell apoptosis. In
fact, overexpression of wild-type Erk5 was found to confer resistance to
PS341-induced cell death. Furthermore, preliminary data obtained in
Figure 7. Erk5 regulates MM apoptosis. (A) Expression of the dominant-negative
form of Erk5 sensitizes MM cells to drug-induced apoptosis. Control () or
HA-Erk5AEF–expressing (f) MM1S cells were plated at identical densities and treated
for 24 hours with the indicated concentrations of PS341 or dexamethasone. MTT
uptake was carried out as described in the text. The results represent the mean SD
of quadruplicates of an experiment repeated twice. (B) Effect of PS341 on myeloma
cells in the presence of bone marrow stromal cells (BMSC). Control or HA-Erk5AEF–
expressing MM1S cells were plated on wells previously coated, or not, with stromal
cells. PS341 (at the indicated concentrations) was added together with the myeloma
cells, and the experiment continued for 48 hours. BrdU was added for the last
8 hours. BrdU uptake was measured as described in “Materials and methods.”  and
f indicate control and HA-Erk5AEF–expressing MM1S cells with BMSC, respectively;
u and p, the same cells without BMSC, respectively. The results represent the
mean  SD of quadruplicates. (C) Action of PS341 on the levels of Erk5. The cell
lines shown were treated with 10 nM PS341 for the indicated times, and then Erk5 or
Erk1/2 levels were analyzed by Western blotting. (D) Effect of different caspase
inhibitors on PS341-induced Erk5 down-regulation. MM1S cells were treated with
PS341 in the presence or absence of the different caspase inhibitors (Z-VAD-FMK,
100 M; Z-IETD-FMK and Z-LEHD-FMK, 50 M) for 8 hours, and then Erk5
expression was analyzed by Western blotting. An aliquot of the cell extract (30 g)
was used to analyze caspase-3 cleavage by Western blotting. DMSO represents
dimethylsulfoxide; Z-VAD-FMK represents Z-Val-Ala-DL-Asp fluoromethylketone;
Z-IETD-FMK represents Z-Ile-Glu-Thr-Asp fluoromethylketone; Z-LEHD-FMK repre-
sents Z-Leu-Glu-His-Asp fluoromethylketone. (E) Effect of Erk5 overexpression on
PS341-induced cell death. Expression of wild-type HA-Erk5 was carried out by
transfection of pCDNA3 or pCDNA3-HA-Erk5 into MM1S cells, followed by G418
selection. A pool of transfected MM1S cells was selected, and the expression of
exogenous HA-Erk5 was detected by Western blotting with anti-HA or with anti-Erk5
(top). The bottom panel shows the effect of PS341 on control or HA-Erk5–
overexpressing MM1S cells. Cells were treated for 24 hours with 10 nM PS341, and
the amount of apoptotic cells analyzed by annexin V–FITC staining. Data are
represented as the mean SD of duplicates of an experiment repeated twice.
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plasma cells from 2 MM patients expressing different levels of Erk5
indicated that low levels of endogenous Erk5 sensitize MM cells to
TNF-regulated apoptosis-inducing ligand (TRAIL)–induced apoptosis
(S.T., X.C.-V., and A.P., unpublished data, May 2004), suggesting that
Erk5 levels may modulate apoptosis in response to TRAIL in myeloma
cells. The mechanism by which Erk5 may exert this action in myeloma
is unclear, but it is noteworthy that in endothelial cells Erk5 has been
shown to phosphorylate Bad, preventing its apoptotic effect.17 In the
future, and due to the resistance of MM cells to apoptosis, it appears
attractive to analyze not only the mechanisms by which the Erk5 route
may regulate such cellular process, but also how it could be exploited to
improve the efficacy of treatments that cause MM cell death.
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